ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries

Diagnostic Microbiology and Infectious Disease

Volumn 64, Issue 2, 2009, Pages 191-201

  Jones, Ronald N ^a   Kohno, Shigeru ^b   Ono, Yasuo ^c   Ross, James E ^a   Yanagihara, Katsunori ^b  

^a JMI LABORATORIES   (United States)

^b NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^c TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

2007; Linezolid; Resistance; Surveillance; ZAAPS

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASIA; AUSTRALIA; BACTERIAL STRAIN; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; BRAZIL; CANADA; CHINA; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; ENTEROCOCCUS; EUROPE; GENE MUTATION; GRAM POSITIVE BACTERIUM; IRELAND; ITALY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SOUTH AND CENTRAL AMERICA; STREPTOCOCCUS PNEUMONIAE;

ACETAMIDES; AGED; ANTI-BACTERIAL AGENTS; ASIA; AUSTRALIA; CANADA; DRUG RESISTANCE, BACTERIAL; EUROPE; FEMALE; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; LATIN AMERICA; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES;

EID: 66449123935     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2009.03.001     Document Type: Article

References (55)

1. Anderegg T.R., Sader H.S., Fritsche T.R., Ross J.E., and Jones R.N. Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program. Int. J. Antimicrob. Agents 26 (2005) 13-21
2. Arias C.A., Vallejo M., Reyes J., Panesso D., Moreno J., Castaneda E., Villegas M.V., Murray B.E., and Quinn J.P. Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase. J. Clin. Microbiol. 46 (2008) 892-896
3. Ballow C.H., Biedenbach D.J., Rossi F., and Jones R.N. Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox(R) Antimicrobial Potency Study in Latin America (LA-ZAPS). Braz. J. Infect. Dis. 6 (2002) 100-109
4. Ballow C.H., Jones R.N., and Biedenbach D.J. A multicenter evaluation of linezolid antimicrobial activity in North America. Diagn. Microbiol. Infect. Dis. 43 (2002) 75-83
5. Bell J.M., Turnidge J.D., Ballow C.H., and Jones R.N. Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific. J. Antimicrob. Chemother. 51 (2003) 339-345
6. Besier S., Ludwig A., Zander J., Brade V., and Wichelhaus T.A. Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances. Antimicrob. Agents Chemother. 52 (2008) 1570-1572
7. Bolmstrom A., Ballow C.H., Qwarnstrom A., Biedenbach D.J., and Jones R.N. Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe). Clin. Microbiol. Infect. 8 (2002) 791-800
8. Brickner S.J. Oxazolidinone antibacterial agents. Current. Pharmacologic. Design 2 (1996) 175-194
9. Chen D.K., McGeer A., de Azavedo J.C., and Low D.E. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N. Engl. J. Med. 341 (1999) 233-239
10. Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-seventh edition, M7-A7 (2006), CLSI, Wayne, PA
11. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial disk susceptibility tests; approved standard-ninth edition, M2-A9 (2006), CLSI, Wayne, PA
12. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement, M100-S18 (2008), CLSI, Wayne, PA
13. Draghi D.C., Sheehan D.J., Hogan P., and Sahm D.F. In vitro activity of linezolid against key gram-positive organisms isolated in the United States: results of the LEADER 2004 surveillance program. Antimicrob. Agents Chemother. 49 (2005) 5024-5032
14. Draghi D.C., Sheehan D.J., Hogan P., and Sahm D.F. Current antimicrobial resistance profiles among methicillin-resistant Staphylococcus aureus encountered in the outpatient setting. Diagn. Microbiol. Infect. Dis. 55 (2006) 129-133
15. Ford C.W., Zurenko G.E., and Barbachyn M.R. The discovery of linezolid, the first oxazolidinone antibacterial agent. Curr. Drug Targets Infect. Disord. 1 (2001) 181-199
16. Fritsche T.R., Castanheira M., Mendes R.E., Jones R.N., and Deshande L.M. Detection of cfr rRNA methyltransferases among Staphylococcus aureus and coagulase-negative staphylococci recovered from human infections, Abstr A-047. 108th American Society for Microbiology General Meeting (ASM), Boston, MA (2008)
17. Gales A.C., Sader H.S., Andrade S.S., Lutz L., Machado A., and Barth A.L. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int. J. Antimicrob. Agents 27 (2006) 300-302
18. Gonzales R.D., Schreckenberger P.C., Graham M.B., Kelkar S., DenBesten K., and Quinn J.P. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357 (2001) 1179
19. Gould I.M. Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus. Int J Antimicrob Agents 31 S2 (2008) 1-16 iii
20. Jones R.N., Johnson D.M., and Erwin M.E. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob. Agents Chemother. 40 (1996) 720-726
21. Jones R.N., Della-Latta P., Lee L.V., and Biedenbach D.J. Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. Dis. 42 (2002) 137-139
22. Jones R.N., Ross J.E., Fritsche T.R., and Sader H.S. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J. Antimicrob. Chemother. 57 (2006) 279-287
23. Jones R.N., Fritsche T.R., Sader H.S., and Ross J.E. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diagn. Microbiol. Infect. Dis. 59 (2007) 309-317
24. Jones R.N., Fritsche T.R., Sader H.S., and Ross J.E. Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries. Diagn. Microbiol. Infect. Dis. 59 (2007) 199-209
25. Jones R.N., Stilwell M.G., Hogan P.A., and Sheehan D.J. Activity of linezolid against 3,251 strains of uncommonly isolated Gram-positive organisms: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother. 51 (2007) 1491-1493
26. Jones R.N., Ross J.E., Castanheira M., and Mendes R. United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagn. Microbiol. Infect. Dis. 62 (2008) 416-426
27. Kollef M.H., Rello J., Cammarata S.K., Croos-Dabrera R.V., and Wunderink R.G. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med. 30 (2004) 388-394
28. Lin D.F., Zhang Y.Y., Wu J.F., Wang F., Zheng J.C., Miao J.Z., Zheng L.Y., Sheng R.Y., Zhou X., Shen H.H.., Ijzerman M.M., cross-Dabrera R.V., and Sheng W. Linezoild for the treatment of infections caused by Gram-positive pathogens in Chine. Int J. Antimicrod Agents 32 (2008) 421-429
29. Long K.S., Poehlsgaard J., Kehrenberg C., Schwarz S., and Vester B. The cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob. Agents Chemother. 50 (2006) 2500-2505
30. Marshall S.H., Donskey C.J., Hutton-Thomas R., Salata R.A., and Rice L.B. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob. Agents Chemother. 46 (2002) 3334-3336
31. Meka V.G., and Gold H.S. Antimicrobial resistance to linezolid. Clin. Infect. Dis. 39 (2004) 1010-1015
32. Mendes R.E., Deshpande L.M., Castanheira M., DiPersio J., Saubolle M.A., and Jones R.N. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob. Agents Chemother. 52 (2008) 2244-2246
33. Moellering R.C. Linezolid: the first oxazolidinone antimicrobial. Ann. Intern. Med. 138 (2003) 135-142
34. Mutnick A.H., Biedenbach D.J., Turnidge J.D., and Jones R.N. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagn. Microbiol. Infect. Dis. 43 (2002) 65-73
35. Mutnick A.H., Enne V., and Jones R.N. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program. Ann. Pharmacother. 37 (2003) 769-774
36. Pai M.P., Rodvold K.A., Schreckenberger P.C., Gonzales R.D., Petrolatti J.M., and Quinn J.P. Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium. Clin. Infect. Dis. 35 (2002) 1269-1272
37. Pillar C.M., Draghi D.C., Sheehan D.J., and Sahm D.F. Prevalence of multidrug-resistant, methicillin-resistant Staphylococcus aureus in the United States: findings of the stratified analysis of the 2004 to 2005 LEADER Surveillance Programs. Diagn. Microbiol. Infect. Dis. 60 (2008) 221-224
38. Potoski B., Adams J., Clarke L., Shutt K., Linden P., Baxter C., Pasculle A., Capitano B., Peleg A., and Szabo D. Epidemiological profile of linezolid-resistant coagulase-negative staphylococci. Clin. Infect. Dis. 43 (2006) 165-171
39. Rahim S., Pillai S.K., Gold H.S., Venkataraman L., Inglima K., and Press R.A. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin. Infect. Dis. 36 (2003) E146-E148
40. Ross J.E., Anderegg T.R., Sader H.S., Fritsche T.R., and Jones R.N. Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program. Diagn. Microbiol. Infect. Dis. 52 (2005) 53-58
41. ® Annual Appraisal of Potency and Spectrum Study. Int. J. Antimicrob. Agents 29 (2007) 295-301
42. Rubinstein E., Cammarata S., Oliphant T., and Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin. Infect. Dis. 32 (2001) 402-412
43. Rubinstein E., Isturiz R., Standiford H.C., Smith L.G., Oliphant T.H., Cammarata S., Hafkin B., Le V., and Remington J. Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob. Agents Chemother. 47 (2003) 1824-1831
44. Shorr A.F., Kunkel M.J., and Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J. Antimicrob. Chemother. 56 (2005) 923-929
45. Spicuzza L., Sciuto C., and La Rosa M. Safety and efficacy of long-term treatment with linezolid in cystic fibrosis: case report. J. Chemother. 20 (2008) 399-401
46. Stevens D.L., Herr D., Lampiris H., Hunt J.L., Batts D.H., and Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 34 (2002) 1481-1490
47. Stevens D.L., Dotter B., and Madaras-Kelly K. A review of linezolid: the first oxazolidinone antibiotic. Expert. Rev. Anti. Infect. Ther. 2 (2004) 51-59
48. Tenover F.C., Williams P.P., Stocker S., Thompson A., Clark L.A., Limbago B., Carey R.B., Poppe S.M., Shinabarger D., and McGowan Jr. J.E. Accuracy of six antimicrobial susceptibility methods for testing linezolid against staphylococci and enterococci. J. Clin. Microbiol. 45 (2007) 2917-2922
49. Toh S.M., Xiong L., Arias C.A., Villegas M.V., Lolans K., Quinn J., and Mankin A.S. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol. Microbiol. 64 (2007) 1506-1514
50. Tsiodras S., Gold H.S., Sakoulas G., Eliopoulos G.M., Wennersten C., Venkataraman L., Moellering R.C., and Ferraro M.J. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358 (2001) 207-208
51. Weigelt J., Itani K., Stevens D., Lau W., Dryden M., and Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 49 (2005) 2260-2266
52. Wolter N., Smith A.M., Farrell D.J., Schaffner W., Moore M., Whitney C.G., Jorgensen J.H., and Klugman K.P. Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. Antimicrob. Agents Chemother. 49 (2005) 3554-3557
53. Wunderink R.G., Cammarata S.K., Oliphant T.H., and Kollef M.H. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin. Ther. 25 (2003) 980-992
54. Wunderink R.G., Rello J., Cammarata S.K., Croos-Dabrera R.V., and Kollef M.H. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124 (2003) 1789-1797
55. Zyvox Package Insert. Pfizer. Available at (2004). http://www.pfizer.com/pfizer/download/uspi_zyvox.pdf